John Marous

Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino.

Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino.

Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino.

Heart Input Output, Inc. provides cloud-based tool using data from electrocardiograms to develop deep learning algorithms focused on individualized predictions through identifying arterial stenosis. It specializes in beat detection, rhythm analysis, disease detection, and Major Adverse Cardiac Events (MACE) risk analysis. The company is headquartered in Pittsburgh, PA.

Gid Bio Inc. develops next-generation cellular therapies for degenerative musculoskeletal, dermal, and organ specific diseases. The company is based in Louisville, CO. The technology uniquely isolates and concentrates a cellular implant that is administered by injection in a physician's office under image guidance. The company has been granted two CPT Class III codes, a step toward Medicare reimbursement. Gid Bio's SVF-2 technology and point-of-care therapy harness the innate power of a patient's own stromal cells. The company was founded in 2010 by Adam J. Katz, G. Patrick Maxwell, Ramon Llull, J. William Futrell. The CEO is William W. Cimino.